Tokiwa-Bio Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$2.61M
- Investors
-
5
Tokiwa-Bio General Information
Description
Operator of a gene therapy company intended to explore the practical application of therapeutic drugs. The company uses artificially synthesized vectors to introduce multiple genes to the cytoplasm without damaging genes in the cell, enabling medical researchers to develop gene therapy drugs for rare diseases such as hemophilia and ischemic diseases.
Contact Information
Website
www.tokiwa-bio.com(Operating Subsidiary)
Corporate Office
- Tsukuba Research Support Center
- 2-1-6 Sengen, Ibaraki
- Tsukuba, 305-0047
- Japan
Corporate Office
- Tsukuba Research Support Center
- 2-1-6 Sengen, Ibaraki
- Tsukuba, 305-0047
- Japan
Tokiwa-Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 20-Oct-2025 | $2.61M | Completed | Pre-Clinical Trials | ||
| 4. Accelerator/Incubator | 13-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 3. Merger/Acquisition | 13-Nov-2017 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 10-Nov-2017 | $2.91M | $2.91M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | Completed | Startup |
Tokiwa-Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A Preferred Shares |
Tokiwa-Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tokiwa-Bio Patents
Tokiwa-Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4524249-A1 | Rna virus-derived chimeric envelope protein and rna virus vector having same | Pending | 25-Apr-2022 | ||
| EP-4524249-A4 | Rna virus-derived chimeric envelope protein and rna virus vector having same | Pending | 25-Apr-2022 | ||
| US-20250340899-A1 | Rna virus-derived chimeric envelope protein and rna virus vector having same | Pending | 25-Apr-2022 | ||
| WO-2023210616-A1 | Rna virus-derived chimeric envelope protein and rna virus vector having same | Inactive | 25-Apr-2022 | ||
| JP-7174958-B2 | Gene expression system using stealth rna and gene introduction/expression vector containing said rna | Active | 16-Jan-2015 | C12N15/85 |
Tokiwa-Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tokiwa-Bio Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Anicom Capital | Venture Capital | Minority | ||
| Japan Science And Technology Agency | Government | Minority | ||
| LINK-J | Accelerator/Incubator | |||
| Nippon Venture Capital | Corporate Venture Capital | Minority |
Tokiwa-Bio FAQs
-
When was Tokiwa-Bio founded?
Tokiwa-Bio was founded in 2014.
-
Where is Tokiwa-Bio headquartered?
Tokiwa-Bio is headquartered in Tsukuba, Japan.
-
What is the size of Tokiwa-Bio?
Tokiwa-Bio has 12 total employees.
-
What industry is Tokiwa-Bio in?
Tokiwa-Bio’s primary industry is Discovery Tools (Healthcare).
-
Is Tokiwa-Bio a private or public company?
Tokiwa-Bio is a Private company.
-
What is Tokiwa-Bio’s current revenue?
The current revenue for Tokiwa-Bio is .
-
How much funding has Tokiwa-Bio raised over time?
Tokiwa-Bio has raised $2.61M.
-
Who are Tokiwa-Bio’s investors?
Anicom Capital, Japan Science And Technology Agency, LINK-J, and Nippon Venture Capital have invested in Tokiwa-Bio.
-
When was Tokiwa-Bio acquired?
Tokiwa-Bio was acquired on 20-Oct-2025.
-
Who acquired Tokiwa-Bio?
Tokiwa-Bio was acquired by FujiFilm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
